Back to School: How biopharma can reboot drug development. Access exclusive analysis here

United Therapeutics up after Viveta data

UTHR gained $25.67 (38%) to $94.11 on Thursday after reporting that Viveta, an inhaled

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE